The Global Neurotrophic Keratitis market accounted for $60.56 million in 2018. A rise in reported cases and a surge in investments in research, clinical studies and product approvals are the major factors propelling market growth. However, on the flipside the high cost of treatment is hampering market growth.
Based on treatment, the drugs segment is set to experience lucrative growth during the forecast period as artificial tears are prescribed for all stages due to their ability to provide wetness and lubrication to the corneal surface and ensure cleanliness. By geography, North America is set to experience strong during the forecast period owing to a rise in product approvals, a well-established health care infrastructure, an increase in technological advancements, a rise in the number of well-equipped laboratories and the presence of key players.
Some of the key players profiled in the the report include Walgreens, ReGenTree, LLC, Novartis AG, Dompefarmaceutici S.p.A., CooperVision, Bayer AG, Bausch & Lomb Incorporated, Allergan, Plc., Abbott Laboratories, Inc. and Johnson & Johnson.
What the report offers:
Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.